Pharmacological molecules have been developed that can target the activity of the negative regulators of the circadian clock to suppress or promote the transcriptional activity of BMAL1 and CLOCK. Depending on the type of cancer, these clock genes may play an oncogenic or tumor-suppressive role. This evidence concerns the gene BMAL1 and cancer.